The company manufactures and trades industrial and medical gases like oxygen and nitrogen, while recently diversifying into software development and engineering services.
The company operates in a commodity-like industry with low returns on capital (ROCE 4.9%) and negative cash conversion, indicating no durable competitive advantage or pricing power. While they claim leadership in medical gases, the financial metrics contradict any structural moat, showing thin margins and poor capital efficiency.
Management is aggressively diversifying into unrelated fields like software and engineering while raising capital through preferential allotments. This 'scattergun' approach, combined with low returns on equity and a lack of dividends, suggests poor discipline in deploying shareholder funds.
The company's collapse was driven by the 'diworsification' into unrelated software and engineering sectors, which drained capital while the core gas business remained a low-return commodity trap. The 2025 income tax search and the auditor's resignation proved to be the first cracks in a crumbling foundation of governance. As interest coverage remained below unity, the firm was unable to service its obligations, and the lack of an audit trail at key branches eventually masked a liquidity crisis that preferential share allotments could no longer plug.
RichFakir rates Hilltone Software & Gases Ltd's business quality as poor — 24/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Hilltone Software & Gases Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Hilltone Software & Gases Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Hilltone Software & Gases Ltd's fair value is about ₹4 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →